VAXDYN SL

Antimicrobial resistance has been identified by the World Health Organization as one of the ten leading global public health threats. Antibiotic-resistant pathogenic bacteria already kill approximately 1.3 million people per year, and projections suggest this figure could grow dramatically in the coming decades unless new therapeutic strategies are developed. Antibiotics — the traditional response to bacterial infections — are losing effectiveness faster than new ones are being developed. VAXDYN has chosen to tackle this problem from the prevention side: rather than developing new antibiotics to be used once an infection has already taken hold, the company is working on the development of vaccines against resistant pathogenic bacteria, with the goal of preventing infections before they occur. This approach is simultaneously more efficient from a public health standpoint and potentially more sustainable economically: preventing an infection is almost always less costly than treating one, particularly when the available therapeutic options are narrowing. VAXDYN's target partners include pharmaceutical companies, biotech firms, healthcare institutions, and clinical communities working in the space of vaccine development and antimicrobial resistance. The B2B model is built around collaboration with pharmaceutical and biotech supply chain partners. VAXDYN operates in a segment where scientific urgency and commercial interest rarely align as directly as they do here, making the proposition particularly compelling for those who take a long-term view of global health.